Allen D. Roses of GlaxoSmithKline to present Data on Neurodegenerative and Psychiatric Diseases, September 18, 2006

MONROVIA, CA – Allen D, Roses, Senior Vice President of Pharmacogenetics for GlaxoSmithKline, will deliver one of three keynote addresses at the 2nd Therapeutic Strategies against Neurodegenerative Conditions Conference in Beltsville, MD. Dr. Roses is a renowned expert on genetics research. He joined GlaxoSmithKline from Duke University in 1997. While at Duke, he led the team that reported susceptibility association of APOE4 with late-onset Alzheimer disease.

Dr. Roses’ presentation entitled, “Translational Genetics - New Targets and Pharmacogenetic Differentiation of Medicines” will take place at 9:45 am on September 18, 2006.

The conference will also feature presentations from Acumen, Amgen, Bristol-Myers Squibb, the Buck Institute for Age Research, Burke-Cornell Medical Research Institute, The Burnham Institute, Columbia University, CytRx, Elan Pharmaceuticals, Eli Lilly, EnVivo Pharmaceuticals, Johns Hopkins University, Memory Pharmaceuticals, Merck Research Laboratories, MGI Pharma, NIH-NIMH, NIH-NINDS, Neurome Inc., Ottawa Health Research Institute, Pfizer, Santori Pharmaceuticals, the University of Alabama at Birmingham, the University of British Colulmbia, the University of North Texas Health Science Center, the University of Rochester School of Medicine, the University of Texas at Dallas, and Wyeth Research Laboratories. The full agenda is available online at www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com